Dublin Internal Medicine Student Society

It was a great event in collaboration with RCSI Emergency Society! Participants got hands on experience to learn about the clinical applications of ultrasound in medicine.

We are so grateful to everyone who attended and we hope to see you all next time!

Welcome back to the DIMSS Digest, where we break down a high-impact clinical trial or guideline into digestible and clinically relevant teaching points — helping you build the skills to interpret, critique, and apply real research to real patients.

This week: Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-2 Trial)

A new New England Journal of Medicine study evaluates whether inhaled treprostinil, a prostacyclin analogue with proposed antifibrotic effects, can slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). In this phase 3 randomized controlled trial, treprostinil significantly reduced decline in forced vital capacity and lowered rates of clinical worsening compared to placebo over 52 weeks, highlighting a potential shift toward targeted, inhaled therapies in fibrotic lung disease. Check out our Google Drive for a full breakdown of the trial, created by the DIMSS Education Team.

Stay tuned every two weeks as we continue unpacking the studies shaping internal medicine — so you can stay sharp for your next ward round.

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2512911

Welcome back to the DIMSS Digest, where we break down a high-impact clinical trial or guideline into digestible and relevant teaching points — helping you build the skills to read, analyze, and apply real research to real patients.

This week: AI-Driven Clinical Decision Support in Acute Ischaemic Stroke

A new BMJ original article explores the clinical benefit of an AI-integrated Clinical Decision Support System (CDSS) for acute ischaemic stroke care compared to usual care, which is the current clinical standard, and investigates whether this digital intervention reduces the risk of new vascular events post-stroke. Check out our new Google Drive for the detailed breakdown of this trial, written by TCD Education Team Member, Kat.
Stay tuned every two weeks as we continue breaking down the studies that shape internal medicine — so that you can stay informed for your next rounds.

Source: Zhang X, Ding L, Jing J, Wang C, Gu H, Jiang Y, et al. Effect of a clinical decision support system on stroke care quality and outcomes in patients with acute ischaemic stroke (GOLDEN BRIDGE II): cluster randomised clinical trial. BMJ. 2026 Mar 21;392:e085810.

DIMSS x RCSI Emergency Society POCUS Workshop!

Join us for a hands-on Point of Care Ultrasound (POCUS) Workshop taking place on Sunday, April 12th!

This event is a collaboration between the Dublin Internal Medicine Student Society (DIMSS) and the RCSI Emergency Medicine Society. The workshop will focus on key clinical internal medicine applications of ultrasound, with an emphasis on practical, hands-on learning. All participants will have the opportunity to practice scanning under guidance.

🕒 Session Times:
10:00–11:00
11:00–12:00

📍 Location:
Floor 3, Mutchnik Lab
26 York Street, RCSI

⚠️ Please note: Places are limited and will be allocated on a first come, first served basis.

Register via this link: https://docs.google.com/forms/d/e/1FAIpQLSex4TBpiOGTquHlzcjZQUhPw3JPONh92KDWnCvnDkfjRLrM2A/viewform

🚨Attention all🚨 Looking to learn about the Canadian medical residence landscape? Look no further.

Join us for a virtual session with Dr. Thoms Holmes, as he shares his journey from medical school to Canadian residency. Dr. Holmes will also be sharing advice, and the session will be followed by a Q&A.

📍Virtual – 30 minute presentation & 30 minute Q&A
🗓️ March 25th 6:00PM

The Zoom link is on the DIMSS Instagram and below!
https://ucd-ie.zoom.us/j/61047387114

Case of the Week!

DIMSS Digest of the Week

DIMSS Case of the Week!

Welcome back to the DIMSS Digest, where we break down a high-impact clinical trial or guideline into digestible and relevant teaching points — helping you build the skills to read, analyze, and apply real research to real patients.

This week: Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

A new NEJM original article explores the clinical benefit of Trastuzumab Deruxtecan as a postneoadjuvant therapy for HER2-Positive Breast Cancer compared to Trastuzumab Emtansine, which is the current standard treatment, and investigate which therapy increases the likelihood of invasive disease-free survival post treatment. Check out our new Google Drive for the detailed breakdown of this trial, written by Education Officer Raghav.

Stay tuned every two weeks as we continue breaking down the studies that shape internal medicine — so that you can stay informed for your next rounds

Source: Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. New England Journal of Medicine. 2025 Dec 10;

Illustration: Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, et al. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy. 2021 Oct;Volume 12:103–14.

Case of the Week: give it a try!

Welcome back to the DIMSS Digest, where we break down a high-impact clinical trial into digestible and clinically relevant teaching points - helping you build the skills to read, analyse, and apply real research to real patients

This week: Ianalumab plus eltrombopag in immune thrombocytopenia (VAYHIT2 trial)

This past 3 randomised trial evaluated whether a short course of Ianalumab, a B-cell-targeting monocloncal antibody, could improve durable disease control in adults with immune thrombocytopenia who relapsed or failed first-line glucocorticoids. The study showed that Ianalumab plus eltrombopag significantly prolonged time to treatment failure and increased sustained platelet responses compared with eltrombopag alone, suggesting a potential disease-modifiying approach that may reduce long-term dependence.

Stay tuned every two weeks as we continue breaking down teh studies shaping internal medicine - so you can stay sharp for your next rounds

Source: Ianalumab plus Eltrombopag in Immune Thrombocytopenia | New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2515168 -citations)